NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Entry into a Material Definitive Agreement

Item1.01

The Patheon Agreements and Packaging Agreement (each as defined
below) described below were not material to Neurocrine
Biosciences, Inc. (the Company) when
executed, but became material to the Company during the quarter
ending June30, 2017.

Master Manufacturing Services Agreement and Product
Agreement

On November28, 2016, the Company and Patheon UK Limited
(Patheon) entered into a Master
Manufacturing Services Agreement (the Services
Agreement) and a related Product Agreement (the
Product Agreement and together with the
Services Agreement, the Patheon
Agreements)for Patheons manufacture of commercial
supplies of INGREZZA^TM
(valbenazine) at Patheons manufacturing site. Under the terms of
the Services Agreement, the Company is responsible for supplying
the active pharmaceutical ingredients for INGREZZA to Patheon.
Patheon is responsible for manufacturing the INGREZZA capsules,
conducting quality control, quality assurance, validation
activities, stability testing, packaging and providing related
services for the manufacture of the INGREZZA capsules.

to the Patheon Agreements, the Company has agreed to order from
Patheon certain annual binding minimum amounts of INGREZZA
capsules in the United States based on an agreed upon pricing
schedule. The Patheon Agreements have an initial term ending
December31, 2021, and will automatically renew after the initial
term for successive terms of two years, unless either party gives
notice of its intention to terminate the Patheon Agreements
within at least 18 months prior to the end of the then current
term.

The Company may terminate the Product Agreement upon 30 days
prior written notice if any governmental agency takes any action
that prevents the Company from importing, exporting, purchasing
or selling INGREZZA. Further, the Company must give at least six
months advance notice (or such shorter period if required to
action taken by a governmental agency) if the Company intends to
no longer order manufacturing services for INGREZZA due to
discontinuance of INGREZZA in the market.

Either party may terminate the Services Agreement or the Product
Agreement (a)if the other party has failed to remedy a material
breach under the Services Agreement or the Product Agreement
within 90 days following receipt of a written notice,
(b)immediately upon written notice to the other party in the
event that the other party is declared insolvent or bankrupt, a
voluntary petition of bankruptcy is filed in any court by such
other party or the Patheon Agreements are assigned by such other
party for the benefit of creditors, and (c)upon six months
written notice if the other party assigns the Services Agreement
or the Product Agreement to an assignee that, in the opinion of
the non-assigning party acting reasonably, is (i)not a credit
worthy substitute for the other party or (ii)a competitor of the
non-assigning party.

The Patheon Agreements contain certain representations,
warranties, limitations of liabilities, confidentiality and
indemnity obligations and other provisions customary for
agreements of their type.

The foregoing description of the terms of the Patheon Agreements
does not purport to be complete and is qualified in its entirety
by reference to the full text of the Services Agreement and the
Product Agreement, copies of which are attached to this report as
Exhibits 99.1 and 99.2, respectively.

Commercial Packaging Agreement

On December12, 2016, the Company and AndersonBrecon Inc., doing
business as PCI of Illinois (PCI),
entered into a Commercial Packaging Agreement (the
Packaging Agreement) for PCIs
commercial packaging services. Under the terms of the Packaging
Agreement, PCI will be responsible for, among other things, the
packaging of certain of the Companys products, tooling purchases
and repair, analytical work, stability testing, auditing of
suppliers and storage. The Company is responsible for supplying
the product materials to PCI. to the Packaging Agreement, the
Company has agreed to submit rolling forecasts, some of which
will be binding on the Company. The Company will compensate PCI
for services rendered, based on an agreed upon fee schedule and
subject to certain price adjustments.

The Packaging Agreement has an initial term ending September30,
2019, unless earlier terminated in accordance with its terms. The
Packaging Agreement will automatically renew after the initial
term for successive terms of two years, unless either party gives
notice of its intention to terminate the Packaging Agreement at
least one year prior to the end of the then current term.

Either party may terminate the Packaging Agreement (a)if the
other party has failed to remedy a material breach within 60 days
following receipt of a written notice, or (b)immediately upon
written notice to the other party in the event that the other
party files a

petition of bankruptcy, enters into an agreement with its
creditors, applies for or consents to the appointment of a
receiver, trustee or administrator, permits the entry of any
order adjudicating it to be bankrupt or insolvent and such order
is not discharged within 30 days, or takes any equivalent action
in consequence of debt in any jurisdiction. Either party may
terminate the Packaging Agreement for any reason or no reason
upon 24 months prior written notice to the other party.

The Packaging Agreement contains certain representations,
warranties, limitations of liabilities, confidentiality and
indemnity obligations and other provisions customary for
agreements of this type.

The foregoing description of the terms of the Packaging Agreement
does not purport to be complete and is qualified in its entirety
by reference to the full text of the Packaging Agreement, a copy
of which is attached to this report as Exhibit 99.3.

License Agreement

Also attached to this report as Exhibit 99.4 is a copy of the
License Agreement between the Company and BIAL Portela CA, S.A.,
dated February9, 2017, the terms of which are described in the
Companys Current Report on Form 8-K that was filed with the
Securities and Exchange Commission on February10, 2017.